Accuracy of the Extent of Axillary Nodal Positivity Related to Primary Tumor Size, Number of Involved Nodes and Number of Nodes Examined
John Han-Chih Chang, MD
OncoLink Assistant Editor
Last Modified: November 1, 1999
Presenter: Rajesh V Iyer, MD
Affiliation: Fox Chase Cancer Center
As radiation therapy's utility becomes more established in the breast conservation and post-mastectomy setting, the issue of axillary lymph node status remains in the forefront in directing treatment recommendations. Specifically, patients with four or more positive axillary lymph nodes are considered at high risk for regional failure, thus leading to the recommendation of RT to the regional lymph nodes in addition to the breast or chest wall. This study examines the relationship of the extent of axillary nodal positivity to primary breast tumor Size, number of involved nodes and number of nodes examined
Materials and Methods:
- In a nearly 20 year span, over 1600 women with stage I - II breast cancer were reviewed.
- All had more than 10 axillary lymph nodes (ALN's) were examined histologically (median = 17)
- A mathematical model was created to estimate the probability of four or more positive lymph nodes in a level I - II dissection.
- The probability of having four or more positive ALN's, when 1 - 3 were found positive in an ALN dissection consisting of a certain number of ALN's taken, was demonstrated in tabular form on the abstract.
- The greater number of ALNs found positive (between 1 - 3) lead to a requirement that a greater number of ALNs be sampled.
- For T1 tumors: A) One ALN positive requires eight or more ALN's must be sampled in order to have 10% or less chance of eventually finding four or more positive ALN's. B) For three ALN's positive, over twenty needs to be sampled to again reduce the risk to less than 10%.
- For T2 tumors: A) One ALN positive requires ten or more ALN's to be sampled in order to have 10% or less chance of having four or more positive. B) For three ALN's positive, even twenty only reduces the rate to 13%.
ASTRO coverage is sponsored, in part, by Varian Medical Systems, Inc.